The next wave of AI value will not ship as an app; it will emerge as entirely new physical possibilities — beyond humanoid robots to deliver breakthrough treatments for cancer and autoimmune diseases on development timelines far shorter than we see today.
This is BioAI: artificial intelligence applied to biological data and problems, enabling faster discoveries in health, medicine, and biotech. BioAI is moving from research labs into real companies, attracting significant funding, and operating under practical constraints. That shift raises challenging questions about risk, governance, partnership strategy, and how to evaluate progress when the outcomes are biological.
Join Johnson School faculty Lutz Finger and Cyriac Roeding, co‑founder and CEO of Earli, for a candid conversation on the shifts shaping AI — and what executives should watch next.
Explore the next frontier, BioAI, through a visionary lens. As always, audience Q&A is welcome.
